Cyclosporine A (CsA) has assumed a central role in the pro-phylaxis of acute graft-versus-host disease after allogenic bone marrow transplantation; however, its potential neurotoxicity can manifest in 10-35% of patients. In most cases, neurotoxicity is transient, but fatal cases have been described. We report a case of acute upbeating nystagmus appearing subsequent to the hematic peak of CsA in a patient undergoing prophylactic treatment for acute graft-versus-host disease after bone marrow transplantation for chronic myeloid leukemia. Computed tomography and magnetic resonance imaging revealed no abnormalities. Although reduced, the upbeating nystagmus persisted over time. To our knowledge, this is the first case in which upbeating nystagm...
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Severe microangiopathy has been reported as a rare complication of cyclosporine A (CsA) prophylaxis ...
Introduction: Drug-resistant epilepsy (DRE) occurs in 20–30% of all patients who develop epilepsy an...
Background: Neurotoxicity is a recognized complication of cyclosporine A (CSA) treatment. The incide...
Eye movement abnormality associated with cyclosporin A 50 year old man developed diplopia 2 months a...
<p><b>Background:</b> Cyclosporine A (CsA) is a widely used immunosuppressive agent that may provoke...
Numerous visual symptoms may occur in patients on cyclosporine, including visual hallucinations, vis...
Central pontine myelinolysis (CPM) has been described as a rare complication of liver transplantatio...
To describe cases of reversible higher cortical disturbance of vision due to Cyclosporine A toxicity...
Severe microangiopathy has been reported as a rare com-plication of cyclosporine A (CsA) prophylaxis...
Imipenem is an antibiotic used with cilastatin in the bone marrow transplant (BMT) setting. Cyclospo...
Background: The aetiology of central nervous system lesions observed in cerebral cyclosporine neurot...
Summary: We report three patients in whom neurologic symptoms and cortical laminar necrosis develope...
Cyclosporine-induced sebaceous hyperplasia (SH) is a well-documented entity, occurring in up to 30% ...
Purpose: Cyclosporine (CsA) is currently widely used as a primary immunosuppressive agent in ocular ...
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Severe microangiopathy has been reported as a rare complication of cyclosporine A (CsA) prophylaxis ...
Introduction: Drug-resistant epilepsy (DRE) occurs in 20–30% of all patients who develop epilepsy an...
Background: Neurotoxicity is a recognized complication of cyclosporine A (CSA) treatment. The incide...
Eye movement abnormality associated with cyclosporin A 50 year old man developed diplopia 2 months a...
<p><b>Background:</b> Cyclosporine A (CsA) is a widely used immunosuppressive agent that may provoke...
Numerous visual symptoms may occur in patients on cyclosporine, including visual hallucinations, vis...
Central pontine myelinolysis (CPM) has been described as a rare complication of liver transplantatio...
To describe cases of reversible higher cortical disturbance of vision due to Cyclosporine A toxicity...
Severe microangiopathy has been reported as a rare com-plication of cyclosporine A (CsA) prophylaxis...
Imipenem is an antibiotic used with cilastatin in the bone marrow transplant (BMT) setting. Cyclospo...
Background: The aetiology of central nervous system lesions observed in cerebral cyclosporine neurot...
Summary: We report three patients in whom neurologic symptoms and cortical laminar necrosis develope...
Cyclosporine-induced sebaceous hyperplasia (SH) is a well-documented entity, occurring in up to 30% ...
Purpose: Cyclosporine (CsA) is currently widely used as a primary immunosuppressive agent in ocular ...
Cyclosporine is a immunosuppressive agent used in solid organ and bone marrow transplantation worldw...
Severe microangiopathy has been reported as a rare complication of cyclosporine A (CsA) prophylaxis ...
Introduction: Drug-resistant epilepsy (DRE) occurs in 20–30% of all patients who develop epilepsy an...